Short Interest in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Decreases By 16.0%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 3,620,000 shares, a drop of 16.0% from the December 15th total of 4,310,000 shares. Based on an average daily volume of 3,270,000 shares, the short-interest ratio is currently 1.1 days.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC purchased a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $727,000. XTX Topco Ltd bought a new stake in shares of Marinus Pharmaceuticals in the second quarter worth $232,000. Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals during the second quarter valued at $28,000. Squarepoint Ops LLC purchased a new stake in Marinus Pharmaceuticals during the second quarter valued at $206,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Marinus Pharmaceuticals in the second quarter valued at about $64,000. 98.80% of the stock is owned by hedge funds and other institutional investors.

Marinus Pharmaceuticals Price Performance

Shares of NASDAQ:MRNS opened at $0.54 on Friday. The business has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $1.00. Marinus Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $10.50.

Wall Street Analysts Forecast Growth

MRNS has been the topic of a number of analyst reports. Royal Bank of Canada dropped their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Oppenheimer raised Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. Jefferies Financial Group restated a “hold” rating and set a $0.50 price target (down from $5.00) on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Finally, HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.